Regulatory approval

Published by the Health Service Executive. Approved

In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

This is written in the approval document.

Reimbursement

Hybrid

Idelalisib - CDS; riTUXimab - Hospital

Citation

Idelalisib and riTUXimab Therapy, 2017, version number 1, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6972/389_v3_idelalisib_and_riTUXimab.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Idelalisib, Rituximab
HSE (1) TP53 Somatic variants Chronic Lymphocytic Leukemia Idelalisib, Rituximab
HSE (1) not 17p deletion Chronic Lymphocytic Leukemia Idelalisib, Rituximab